Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

[D.ap]

The forum is organized with this section , "other publications"
being reserved for papers not specific to ASPS. However , my wish and hope is to soon make it a post for ASPS
My friends , some "light " reading for the weekend .



Volume 161, Issue 2, 9 April 2015, Pages 205-214
Review
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential



http://www.sciencedirect.com/science/ar ... 7415003177

[D.ap]

"Although it is clear that clinical responses can be elicited with immune checkpoint therapies or genomically targeted agents, it appears that genomically targeted agents alone tend to improve median survival without providing long-term durable responses (Figure 2, blue line). Targeting immune checkpoints improves median survival but remarkably also provides long-term durable responses, raising the tail of the survival curve (Figure 2, green line). When combined, these therapies are likely to have an additive or even synergistic therapeutic effect that not only would potentially further improve median survival but would also raise the tail of the survival curve, increasing the number of patients that appreciate long-term clinical benefit (Figure 2, red line)."